This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.

Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.


1h1d

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 1: Line 1:
-
[[Image:1h1d.gif|left|200px]]
+
{{Seed}}
 +
[[Image:1h1d.png|left|200px]]
<!--
<!--
Line 9: Line 10:
{{STRUCTURE_1h1d| PDB=1h1d | SCENE= }}
{{STRUCTURE_1h1d| PDB=1h1d | SCENE= }}
-
'''CATECHOL O-METHYLTRANSFERASE'''
+
===CATECHOL O-METHYLTRANSFERASE===
-
==Overview==
+
<!--
-
Catechol-O-methyltransferase (COMT; E.C. 2.1.1.6) is a ubiquitous enzyme in nature that plays an important role in the metabolism of catechol neurotransmitters and xenobiotics. In particular, inactivation of drugs such as L-3,4-dihydroxyphenylalanine (L-DOPA) via O-methylation is of relevant pharmacological importance, because L-DOPA is currently the most effective drug used in the treatment of Parkinson's disease. This justified the interest in developing COMT inhibitors as potential adjuncts to L-DOPA therapy. The kinetics of inhibition by BIA 3-335 (1-[3,4-dihydroxy-5-nitrophenyl]-3-(N-3'-trifluormethylphenyl)-piperazine- 1-propanone dihydrochloride) were characterized using recombinant rat soluble COMT. BIA 3-335 was found to act as a potent, reversible, tight-binding inhibitor of COMT with a K(i) of 6.0 +/- 1.6 nM and displaying a competitive inhibition toward the substrate binding site and uncompetitive inhibition toward the S-adenosyl-L-methionine (SAM) binding site. The 2.0-A resolution crystal structure of COMT in complex with its cosubstrate SAM and a novel inhibitor BIA 3-335 shows the atomic interactions between the important residues at the active site and the inhibitor. This is the first report of a three-dimensional structure determination of COMT complexed with a potent, reversible, and tight-binding inhibitor that is expected to have therapeutic applications.
+
The line below this paragraph, {{ABSTRACT_PUBMED_12237326}}, adds the Publication Abstract to the page
 +
(as it appears on PubMed at http://www.pubmed.gov), where 12237326 is the PubMed ID number.
 +
-->
 +
{{ABSTRACT_PUBMED_12237326}}
==About this Structure==
==About this Structure==
Line 32: Line 36:
[[Category: Methyltransferase]]
[[Category: Methyltransferase]]
[[Category: Neurotransmitter degradation]]
[[Category: Neurotransmitter degradation]]
-
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Fri May 2 18:17:39 2008''
+
 
 +
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Tue Jul 1 06:27:40 2008''

Revision as of 03:27, 1 July 2008

Image:1h1d.png

Template:STRUCTURE 1h1d

CATECHOL O-METHYLTRANSFERASE

Template:ABSTRACT PUBMED 12237326

About this Structure

1H1D is a Single protein structure of sequence from Rattus norvegicus. Full crystallographic information is available from OCA.

Reference

Kinetics and crystal structure of catechol-o-methyltransferase complex with co-substrate and a novel inhibitor with potential therapeutic application., Bonifacio MJ, Archer M, Rodrigues ML, Matias PM, Learmonth DA, Carrondo MA, Soares-Da-Silva P, Mol Pharmacol. 2002 Oct;62(4):795-805. PMID:12237326

Page seeded by OCA on Tue Jul 1 06:27:40 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA

Retrieved from "http://52.214.119.220/wiki/index.php/1h1d"
Personal tools